Dataset: Search for specific biomarkers of IFN-beta bioactivity in patients with MS

We aimed to identify specific biomarkers of IFN-beta bioactivity in order to compare their gene expression induction by type I IFNs with...

Registered by ArrayExpress Uploader

View Dataset

We aimed to identify specific biomarkers of IFN-beta bioactivity in order to compare their gene expression induction by type I IFNs with the MxA, and to investigate their potential role in MS pathogenesis. Gene expression microarrays were performed in PBMC from MS patients who developed neutralizing antibodies (NAB) to IFN-beta. Nine genes followed patterns in gene expression over time similar to the MX1 and were selected for further experiments: IFI6, IFI27, IFI44L, IFIT1, HERC5, LY6E, RSAD2, SIGLEC1, and USP18. In vitro experiments revealed specific induction of selected biomarkers by IFN-beta but not IFN-gamma, and several markers, in particular USP18 and HERC5, were significantly induced at lower IFN-beta concentrations and more selective than the MX1 as biomarkers of IFN-beta bioactivity. In addition, USP18 expression was deficient in MS patients compared with healthy controls (p=0.0004). We propose specific biomarkers that may be considered in addition to the MxA to evaluate IFN-beta bioactivity, and to further explore their implication in MS pathogenesis. Number of samples: 32. We analyzed PBMC from 8 patients at baseline and after 3, 12 and 24 months of IFN-beta treatment

Species:: human
Samples:: 32
Source:: E-GEOD-26104
Updated:: Dec.12, 2014
Registered:: Sep.15, 2014

Factors: (via ArrayExpress)

Sample	AGE	INDIVIDUAL	TREATMENT	TIME
GSM641342	53	Patient 4	baseline	baseline
GSM641343	53	Patient 4	BETAFERON	3 month of BETAFERON
GSM641344	53	Patient 4	BETAFERON	12 month of BETAFERON
GSM641345	53	Patient 4	BETAFERON	24 month of BETAFERON
GSM641346	52	Patient 13	baseline	baseline
GSM641347	52	Patient 13	REBIF	3 month of REBIF
GSM641348	52	Patient 13	REBIF	12 month of REBIF
GSM641349	52	Patient 13	REBIF	24 month of REBIF
GSM641350	50	Patient 999	baseline	baseline
GSM64135	50	Patient 999	BETAFERON	3 month of BETAFERON
GSM641352	50	Patient 999	BETAFERON	12 month of BETAFERON
GSM641353	50	Patient 999	BETAFERON	24 month of BETAFERON
GSM641354	50	Patient 998	baseline	baseline
GSM641355	50	Patient 998	BETAFERON	3 month of BETAFERON
GSM641356	50	Patient 998	BETAFERON	12 month of BETAFERON
GSM641357	50	Patient 998	BETAFERON	24 month of BETAFERON
GSM641358	33	Patient 108	baseline	baseline
GSM641359	33	Patient 108	BETAFERON	3 month of BETAFERON
GSM641360	33	Patient 108	BETAFERON	12 month of BETAFERON
GSM64136	33	Patient 108	BETAFERON	24 month of BETAFERON
GSM641362	35	Patient 112	baseline	baseline
GSM641363	35	Patient 112	REBIF	3 month of REBIF
GSM641364	35	Patient 112	REBIF	12 month of REBIF
GSM641365	35	Patient 112	REBIF	24 month of REBIF
GSM641366	36	Patient 113	baseline	baseline
GSM641367	36	Patient 113	REBIF	3 month of REBIF
GSM641368	36	Patient 113	REBIF	12 month of REBIF
GSM641369	36	Patient 113	REBIF	24 month of REBIF
GSM641370	36	Patient 116	baseline	baseline
GSM64137	36	Patient 116	REBIF	3 month of REBIF
GSM641372	36	Patient 116	REBIF	12 month of REBIF
GSM641373	36	Patient 116	REBIF	24 month of REBIF